These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 34735255)
1. RNA drugs custommade for rare diseases face wider test. Kaiser J Science; 2021 Nov; 374(6568):672. PubMed ID: 34735255 [No Abstract] [Full Text] [Related]
2. Challenges in orphan drug development and regulatory policy in China. Cheng A; Xie Z Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254 [TBL] [Abstract][Full Text] [Related]
3. New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals. Velho RV; Sperb-Ludwig F; Schwartz IV An Acad Bras Cienc; 2015 Aug; 87(2 Suppl):1375-88. PubMed ID: 26247150 [TBL] [Abstract][Full Text] [Related]
4. Optimal therapy for rare disorders and genetic diseases: ethical and political challenges. MacLeod S Proc West Pharmacol Soc; 2007; 50():21-3. PubMed ID: 18605224 [TBL] [Abstract][Full Text] [Related]
6. Managing drugs for rare genetic diseases: trends and insights. Zitter M Manag Care; 2005 Feb; 14(2):52-4, 57-60, 63-4; quiz 66-7. PubMed ID: 15782848 [TBL] [Abstract][Full Text] [Related]
7. Drug discovery and development for rare genetic disorders. Sun W; Zheng W; Simeonov A Am J Med Genet A; 2017 Sep; 173(9):2307-2322. PubMed ID: 28731526 [TBL] [Abstract][Full Text] [Related]
16. Rare diseases and orphan drugs. Melnikova I Nat Rev Drug Discov; 2012 Mar; 11(4):267-8. PubMed ID: 22460117 [No Abstract] [Full Text] [Related]
17. Promoting the development of drugs against rare diseases: what more should be done? Westermark K; Llinares J Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396 [No Abstract] [Full Text] [Related]